Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Selective androgen receptor modulator
RAD140
Другие языки:

RAD140

Подписчиков: 0, рейтинг: 0
RAD140
RAD140.svg
Identifiers
  • 2-chloro-4-{[(1R,2S)-1-[5-(4-cyanophenyl)-1,3,4-oxadiazol-2-yl]-2-hydroxypropyl]amino}-3-methylbenzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C20H16ClN5O2
Molar mass 393.83 g·mol−1
3D model (JSmol)
  • ClC1=C(C#N)C=CC(=C1C)N[C@H]([C@H](C)O)C2=NN=C(O2)C3=CC=C(C=C3)C#N
  • InChI=1S/C20H16ClN5O2/c1-11-16(8-7-15(10-23)17(11)21)24-18(12(2)27)20-26-25-19(28-20)14-5-3-13(9-22)4-6-14/h3-8,12,18,24,27H,1-2H3/t12-,18+/m0/s1
  • Key:XMBUPPIEVAFYHO-KPZWWZAWSA-N

RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.

Clinical trials

The first-in-human study was initiated in October of 2017 and completed in September 2020 in postmenopausal women with breast cancer.

In early 2020 a single case report of drug-induced liver injury following use of RAD 140 was published.

Animal studies

RAD 140 appears to be safer than testosterone replacement therapy (TRT) in rats.

RAD 140 slightly increased lean muscle mass when used in primates, by targeting androgen receptors in skeletal tissue.

See also


Новое сообщение